<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Pavmed Inc — News on 6ix</title>
<link>https://6ix.com/company/pavmed-inc</link>
<description>Latest news and press releases for Pavmed Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 14:23:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/pavmed-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a8db78dffbe2df10c882.webp</url>
<title>Pavmed Inc</title>
<link>https://6ix.com/company/pavmed-inc</link>
</image>
<item>
<title>Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-closing-of-dollar18-million-underwritten-offering-of-common-stock-1</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-closing-of-dollar18-million-underwritten-offering-of-common-stock-1</guid>
<pubDate>Fri, 24 Apr 2026 14:23:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder.</description>
</item>
<item>
<title>Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-dollar18-million-underwritten-offering-of-common-stock-1</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-dollar18-million-underwritten-offering-of-common-stock-1</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder.</description>
</item>
<item>
<title>Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Thu, 09 Apr 2026 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.</description>
</item>
<item>
<title>PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-84</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-84</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed</description>
</item>
<item>
<title>PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-30-2026</guid>
<pubDate>Mon, 16 Mar 2026 13:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Den</description>
</item>
<item>
<title>Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-11</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-11</guid>
<pubDate>Thu, 12 Mar 2026 13:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath</description>
</item>
<item>
<title>PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-closes-preferred-stock-senior-130100514</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-closes-preferred-stock-senior-130100514</guid>
<pubDate>Wed, 04 Feb 2026 13:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced the closing of preferred stock and senior secured note financings by existing long-term investors, resulting in the elimination of a significant legacy capital structure overhang from previously outstanding convertible securities and a materially strengthened balance sheet.</description>
</item>
<item>
<title>Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-awarded-us-department-of-veterans-affairs-contract-for-esoguardr</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-awarded-us-department-of-veterans-affairs-contract-for-esoguardr</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually.</description>
</item>
<item>
<title>PAVmed Announces Reverse Stock Split</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-announces-reverse-stock-split-140100905</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-announces-reverse-stock-split-140100905</guid>
<pubDate>Tue, 30 Dec 2025 14:01:00 GMT</pubDate>
<description>PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM</description>
</item>
<item>
<title>Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-positive-data-from-the-largest-reported-real-world-experience-of-esophageal-precancer-detection</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-announces-positive-data-from-the-largest-reported-real-world-experience-of-esophageal-precancer-detection</guid>
<pubDate>Tue, 09 Dec 2025 13:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer (Barrett's esophagus or BE) detection, which evaluated its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. The manuscript, entitled Non-Endoscopic Screening for Barrett's Esophagu</description>
</item>
<item>
<title>Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-named-a-genomeweb-2025-best-places-to-work-top-ranking-honoree</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-named-a-genomeweb-2025-best-places-to-work-top-ranking-honoree</guid>
<pubDate>Thu, 20 Nov 2025 13:15:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named the winner in its company size category of the GenomeWeb 2025 Best Places to Work program, one of five top-ranking honorees across the life sciences research, diagnostics and precision medicine sectors.</description>
</item>
<item>
<title>PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-provides-business-reports-third-130000413</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-provides-business-reports-third-130000413</guid>
<pubDate>Thu, 13 Nov 2025 13:00:00 GMT</pubDate>
<description>PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended September 30, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-provides-business-update-and-reports-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-provides-business-update-and-reports-third-quarter-2025-financial-results</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended September 30, 2025.</description>
</item>
<item>
<title>PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-hold-business-conference-call-120100695</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-hold-business-conference-call-120100695</guid>
<pubDate>Thu, 30 Oct 2025 12:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy</description>
</item>
<item>
<title>Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-12-2025</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-12-2025</guid>
<pubDate>Wed, 29 Oct 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy.</description>
</item>
<item>
<title>Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-participate-in-the-2025-maxim-growth-summit</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-to-participate-in-the-2025-maxim-growth-summit</guid>
<pubDate>Wed, 15 Oct 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2025 Maxim Growth Summit, being held October 22-23, 2025 in New York City.</description>
</item>
<item>
<title>PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement</title>
<link>https://6ix.com/company/pavmed-inc/news/pavmed-subsidiary-veris-health-ohio-120100473</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/pavmed-subsidiary-veris-health-ohio-120100473</guid>
<pubDate>Tue, 07 Oct 2025 12:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensi</description>
</item>
<item>
<title>Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors</title>
<link>https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-appoints-healthcare-industry-veteran-john-r-palumbo-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/pavmed-inc/news/lucid-diagnostics-appoints-healthcare-industry-veteran-john-r-palumbo-to-board-of-directors</guid>
<pubDate>Thu, 25 Sep 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025.</description>
</item>
</channel>
</rss>